Abstract：
UNASSIGNED: Long-term real-life data on secukinumab use in psoriasis are limited.
UNASSIGNED: Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life.
UNASSIGNED: Multicenter retrospective study analyzing data from adult patients treated with secukinumab for at least 192 weeks and up to 240 weeks in Southern Italy, between 2016 and 2021. Clinical data, including concurrent comorbidities and prior treatments were collected. Effectiveness was assessed by Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) scores at the initiation of secukinumab and at weeks 4, 12, 24, 48, 96, 144, 192, and 240.
UNASSIGNED: Two hundred and seventy-five patients (174 males), mean age 50.80 ± 14.78 years, were included; 29.8% had an uncommon localization, 24.4% psoriatic arthritis, 71.6% comorbidities. PASI, BSA, and DLQI improved significantly from week 4 and continued to improve over time. Between weeks 24 and 240, PASI score was mild (≤10) in 97-100% of patients, 83-93% had mild affected BSA (BSA ≤ 3), and 62-90% reported no effect of psoriasis on their quality of life (DLQI 0-1). Only 2.6% of patients reported adverse events and no patient discontinued the treatment during the study period.
UNASSIGNED: Secukinumab effectiveness in the long-term treatment of psoriasis is confirmed in real-world.
UNASSIGNED: Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life.
UNASSIGNED: Multicenter retrospective study analyzing data from adult patients treated with secukinumab for at least 192 weeks and up to 240 weeks in Southern Italy, between 2016 and 2021. Clinical data, including concurrent comorbidities and prior treatments were collected. Effectiveness was assessed by Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) scores at the initiation of secukinumab and at weeks 4, 12, 24, 48, 96, 144, 192, and 240.
UNASSIGNED: Two hundred and seventy-five patients (174 males), mean age 50.80 ± 14.78 years, were included; 29.8% had an uncommon localization, 24.4% psoriatic arthritis, 71.6% comorbidities. PASI, BSA, and DLQI improved significantly from week 4 and continued to improve over time. Between weeks 24 and 240, PASI score was mild (≤10) in 97-100% of patients, 83-93% had mild affected BSA (BSA ≤ 3), and 62-90% reported no effect of psoriasis on their quality of life (DLQI 0-1). Only 2.6% of patients reported adverse events and no patient discontinued the treatment during the study period.
UNASSIGNED: Secukinumab effectiveness in the long-term treatment of psoriasis is confirmed in real-world.
摘要：
背景关于苏金单抗在银屑病中使用的长期真实数据是有限的。目的确定苏金单抗在现实生活中的中重度银屑病中的长期有效性。方法多中心回顾性研究分析了在意大利南部接受苏金单抗治疗至少192周和长达240周的成年患者的数据，2016年至2021年。临床数据,包括并发合并症和之前的治疗收集。通过银屑病面积和严重程度指数(PASI)评估疗效，体表面积(BSA),苏金单抗开始时和第4、12、24、48、96、144、192和240周的皮肤病学生活质量指数（DLQI）评分。结果275例患者（男性174例），平均年龄50.80±14.78岁，包括在内；29.8%的人有不寻常的本地化，24.4%银屑病关节炎,71.6%的合并症。PASI,BSA,和DLQI从第4周开始显着改善，并且随着时间的推移继续改善。在第24周和240周之间，97-100％的患者的PASI评分为轻度（≤10），83-93％患有轻度感染的BSA（BSA≤3），62-90%报告银屑病对其生活质量无影响(DLQI0-1)。只有2.6%的患者报告了不良事件，在研究期间没有患者停止治疗。结论在真实世界中证实了Secukinumab在银屑病的长期治疗中的有效性。
